d'Amato C C, Pizza V, Marmolo T, Giordano E, Alfano V, Nasta A
Headache Center, Neurological Institute, Second University of Naples, Italy.
Headache. 1999 Nov-Dec;39(10):716-9. doi: 10.1046/j.1526-4610.1999.3910716.x.
Selective serotonin reuptake inhibitors have recently been used in the treatment of migraine.
We studied the safety and efficacy of fluoxetine in the prevention of migraine.
Between February 1997 and December 1997, we examined 52 patients (33 women) at the Headache Diagnosis and Therapy Service of the Second University of Naples. Ages ranged from 18 to 65 years, and all patients suffered from migraine without aura according to IHS 1988 criteria. The sample was divided into two groups: group A included 32 patients (19 women; mean age, 36.8 years [SD 12.4]) who received fluoxetine at a dosage of 20 mg per day; group B included 20 patients (14 women; mean age, 38.8 years [SD 15.6]) who received placebo.
Our study was a single-center, randomized, double-blind, parallel study of fluoxetine for the prophylactic control of migraine and consisted of two phases: 30 days of pharmacological wash out and 6 months of therapy with monthly follow-up. Patients were randomly assigned to two groups: A, fluoxetine or B, placebo. At the first visit, patients provided a detailed history and underwent neurological evaluation and a Zung test for depression. No pathological values were revealed. In order to monitor symptomatology, all patients received a form for the calculation of the total pain index at monthly follow-up.
A comparison of the total pain index between basal values (calculated during the period of wash out) and monthly follow-up (calculated monthly during the period of 6 months of the therapy) showed significant reduction (P < .05) beginning from the third month of treatment in the fluoxetine group and no significant reduction in the placebo group.
Even if preliminary and to be confirmed, these data seem to support the use of fluoxetine in the treatment of migraine.
选择性5-羟色胺再摄取抑制剂最近已用于偏头痛的治疗。
我们研究了氟西汀预防偏头痛的安全性和有效性。
在1997年2月至1997年12月期间，我们在那不勒斯第二大学头痛诊断与治疗中心检查了52例患者（33例女性）。年龄在18至65岁之间，所有患者均根据1988年国际头痛协会（IHS）标准患有无先兆偏头痛。样本分为两组：A组包括32例患者（19例女性；平均年龄36.8岁[标准差12.4]），他们接受每日20毫克剂量的氟西汀治疗；B组包括20例患者（14例女性；平均年龄38.8岁[标准差15.6]），他们接受安慰剂治疗。
我们的研究是一项关于氟西汀预防性控制偏头痛的单中心、随机、双盲、平行研究，包括两个阶段：30天的药物洗脱期和6个月的治疗期，每月随访。患者被随机分为两组：A组为氟西汀组，B组为安慰剂组。在首次就诊时，患者提供详细病史，并接受神经学评估和抑郁的zung测试。未发现病理值。为了监测症状，所有患者在每月随访时都收到一份用于计算总疼痛指数的表格。
比较基础值（在洗脱期计算）和每月随访值（在6个月治疗期每月计算）之间的总疼痛指数，结果显示，从氟西汀组治疗的第三个月开始有显著降低（P < 0.05），而安慰剂组无显著降低。
即使这些数据是初步的且有待证实，但似乎支持氟西汀用于偏头痛的治疗。
